Research funded by the federal government has been crucial in many of the defining technologies of our time: the internet, A.I., CRISPR, Ozempic, and the mRNA vaccines that saved untold lives during the COVID pandemic. Between 2010 and 2019, more than 350 drugs were approved in the United States, and virtually all of them could trace their roots to the National Institutes of Health (NIH). Now the current administration in Washington is endangering our health by cutting funds to medical schools, research labs, and biotech firms. Medical schools have paused hiring; labs are letting employees go; universities are curtailing Ph.D. programs. Biotech investors are warning of a contraction in medical innovation. Clinical trials are shutting down—and will fill the graveyards with those who were given hope.

Join us for a timely talk by Monica Gandhi, M.D., M.P.H., a professor of medicine and associate chief in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco (UCSF). She is also the director of the UCSF Center for AIDS Research (CFAR) and the medical director of the HIV Clinic ("Ward 86") at San Francisco General Hospital. She serves as the associate program director of the ID fellowship at UCSF. Her research focuses on HIV treatment and prevention optimization, HIV and women, adherence measurement in HIV and TB, adherence interventions, and optimizing the use of long-acting antiretroviral therapy (ART).